Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Neurodevelopmental disability is the most significant complication for survivors of infant
surgery for congenital heart disease. In this study we sought to determine if intraoperative
continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12
months.